← The Wire·Earnings··2 outlets

Immix reports 89% complete-response rate in 25 NEXICART-2 patients

Immix Biopharma reported an 89% complete-response rate in an interim update covering all NEXICART-2 patients. The MRD-negative results create a near-term clinical catalyst around whether the therapy can sustain its potential efficacy in relapsed disease.

The story

Immix Biopharma said 21 of 25 new patients in the NEXICART-2 study were in complete response at the interim update, while the remaining four were MRD-negative. That means all 25 patients were either in complete response or MRD-negative, according to the company’s announcement.

The reported 89% complete-response rate applies across the patients covered by the update; the MRD-negative findings support the company’s statement that the rate could reach up to 98% when those cases are considered. The update concerns NEXICART-2, an investigational therapy for relapsed disease.

The result touches Immix Biopharma through the clinical-development value of NEXICART-2 and any later regulatory or commercial pathway for the therapy. The concrete mechanism is clinical: response durability, the significance of MRD negativity and subsequent study outcomes will determine how the interim data translate into a treatment profile.

The figures are interim rather than a completed clinical readout, and the announcement describes the 98% figure as potential. The sample cited here is 25 new patients, so the final interpretation depends on follow-up and later clinical evidence.

The next milestones are additional NEXICART-2 follow-up, a fuller study update and any regulatory interaction or filing tied to the program. Response durability, the persistence of MRD negativity and the eventual size of the evaluable dataset are the key facts that would settle the clinical read.

Our read · Tue, Sep 29

IMMX reported 21 complete responses among 25 new NEXICART-2 patients, with four more MRD-negative.

Why. The interim efficacy signal could materially change how the market values NEXICART-2, but the decisive evidence is durability and confirmation beyond the 25-patient update. The clinical read is constructive, while the lack of a dated next milestone and the interim sample argue against a directional call here.

Both cases

The case it holdsThe reported 21 complete responses plus four MRD-negative patients gives NEXICART-2 a strong early efficacy profile and supports Immix’s potential best-in-class positioning.
The case it breaksThe evidence is still interim and limited to 25 new patients, with the 98% figure explicitly framed as potential rather than an established final result.

What could change this view: The read fails if later follow-up shows responses are not durable or if subsequent study results do not reproduce the interim signal.

Immx stock page →
Your side is graded privately against closes after 10 trading days. Research, not advice.

Who reported it · 2

Keep reading

Latest on the Wire

Iran claims strikes on two US bases in Bahrain as Trump line is testedTrump calls Russian missiles in Poland mistakes before fresh incursionAmazon nears $7.5bn Decart deal as AWS takes on Nvidia in AI computingRussian cargo ship Sparta II reportedly hit by drones near FinlandBTCS warns $54 million Aave loan faces liquidation as ether fallsContinue on the Wire →

Top this week

Nvidia allies lobby board to bring back Jensen Huang as CEONvidia chair rules out Huang return as CEO after 75% sales outlookAnthropic Said to Guide IPO Pricing Above Market RangeNvidia interim CEO Colette Kress faces first earnings test after HuangAnthropic IPO could become the largest in US history on Thursday
The Wire at 7 AM ET, free. Top stories with a bull and a bear case on each, every morning. No account needed.

About this report

Reported by GlobeNewswire as Immix Biopharma Announces 89% Complete Response Rate at Interim Update Across All NEXICART-2 Patients, with MRD-Negativity Indicating Potential to Reach up to 98% Complete Response Rate, Supporting Potential Best-in-Class Therapy for Relaps, . Who answers for this

2 reports from 1 publisher in this record. Closes are licensed end-of-day data from Databento; the move after a story is its first close against the close before it. How this is decided →

Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →